Evidence map›Paper›PMID 40132227›Full record

ReviewAnnual review of biochemistry2025

Endothelial Glycocalyx Turnover in Vascular Health and Disease: Rethinking Endothelial Dysfunction.

Alejandro Gomez Toledo, Gregory J Golden, Richard D Cummings, Johan Malmström, Jeffrey D Esko

Abstract readReview
In one paragraph

Review in Annual review of biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Observational
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell-Based Therapies.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Endothelial Surface Glycocalyx in Vascular Functions and Diseases.Advances in experimental medicine and biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alejandro Gomez ToledoDepartment of Clinical Sciences, Lund University, Lund, Sweden.
Gregory J GoldenDepartment of Cellular and Molecular Medicine and Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California, USA; email: jesko@health.ucsd.edu.
Richard D CummingsDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Johan MalmströmDepartment of Clinical Sciences, Lund University, Lund, Sweden.
Jeffrey D EskoDepartment of Cellular and Molecular Medicine and Glycobiology Research and Training Center, University of California, San Diego, La Jolla, California, USA; email: jesko@health.ucsd.edu.

Funding

Protein Glycosylation in the Coagulopathy and Inflammation of SepsisP01HL131474 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MARTH, JAMEY · 2016 to 2025
$26.2M
Siglec Modulation of Inflammation in Humans and MiceP01HL057345 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 1997 to 2012
$24.1M
NHLBI NIH HHS P01 HL057345NHLBI NIH HHS P01 HL131474
6 · The paper itself

Abstract

The endothelial glycocalyx, a glycan-rich layer on the luminal surface of endothelial cells lining blood and lymphatic vessels, plays a crucial role in vascular homeostasis by regulating vascular permeability, immune cell trafficking, and vascular tone. Dysregulated endothelial glycocalyx turnover-whether through altered synthesis, intracellular degradation, or shedding-contributes to endothelial dysfunction in conditions such as sepsis, ischemic events, and chronic inflammatory disorders including diabetes and atherosclerosis. In this review, we examine the structure, function, and turnover of the endothelial glycocalyx, emphasizing how pathological changes in its turnover drive vascular dysfunction. We also highlight diagnostic approaches to evaluate dysregulated endothelial glycocalyx turnover in connection with vascular diseases and discuss therapeutic strategies aimed at preventing endothelial glycocalyx degradation and restoring endothelial function.

Indexed as

AtherosclerosisEndothelial CellsEndothelium, VascularGlycocalyxVascular DiseasesAnimalsCapillary PermeabilityHumansSepsisendotheliumextracellular matrixglycocalyxinfectioninflammationvasculature

Identifiers

PMID40132227
PMCPMC13377631

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.